Radovich Peter 4

Accession 0001650131-26-000002

CIK 0001759425other

Filed

Jan 22, 7:00 PM ET

Accepted

Jan 23, 5:30 PM ET

Size

9.1 KB

Accession

0001650131-26-000002

AI-generated summary of this filing

Updated Jan 23, 2026

Mirum (MIRM) President Peter Radovich Sells Shares

What Happened

Peter Radovich, President and COO of Mirum Pharmaceuticals (MIRM), had 4,167 restricted stock units (RSUs) convert to common stock on 2026-01-21 (exercise/conversion of derivative). A portion of the resulting shares were sold: 2,382 shares were sold in an open-market transaction on 2026-01-22 at $93.33 per share, generating $222,301. The RSU conversion is recorded at $0.00 (typical for RSUs).

Key Details

Transaction dates: RSU conversion 2026-01-21; open-market sale 2026-01-22; Form 4 filed 2026-01-23.
Sale: 2,382 shares at $93.33 = $222,301 total.
RSU conversion: 4,167 shares converted (recorded at $0.00); some shares were disposed to cover tax withholding.
Shares owned after the transactions: not specified in the provided filing excerpt.
Relevant footnotes:
- F1: Each RSU equals a contingent right to one share (or cash at issuer’s discretion).
- F3: Shares sold to cover tax withholding from RSU vesting.
- F4: RSUs vest 1/3 each year from Jan 21, 2025 (three-year schedule).
- F2: Includes 222 shares acquired via the Employee Stock Purchase Plan on Nov 10, 2025.
Filing timeliness: Form 4 was filed 2026-01-23 for activity on 2026-01-21/22 — appears to be timely (no late filing indicated).

Context

These were RSU vesting-related actions, not an outright market purchase. The RSU conversion at $0.00 reflects issuance on vesting rather than an option exercise with a cash strike.
The open-market sale appears to have been used in part to satisfy tax-withholding obligations (routine administrative action), which is common when RSUs vest and does not necessarily indicate a change in insider sentiment.

Form 4

Period: 2026-01-21

PRESIDENT AND COO

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-01-21+4,167→ 23,061 total
Sale
Common Stock
[F3]
2026-01-22$93.33/sh−2,382$222,301→ 20,679 total
Exercise/Conversion
Restricted Stock Units
[F1][F4]
2026-01-21−4,167→ 8,333 total
→ Common Stock (4,167 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).
[F2]Includes 222 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan.
[F3]Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
[F4]1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.

Signature

/s/ Judit Ryvkin, Attorney-in-Fact|2026-01-23

1 file

Mirum Pharmaceuticals, Inc.

CIK 0001759425

Entity typeother